Non-Hodgkin’s Lymphoma And Chronic Lymphocytic Leukemia – Emerging Therapies – Venclexta Launch Tracking (US) Wave 1

LaunchTrends: Venclexta (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic lymphocytic leukemia (CLL) drug Venclexta (Roche/AbbVie’s venetoclax). LaunchTrends: Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. The report evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity of Venclexta.

Questions Answered:

  • What are the awareness of and familiarity with Venclexta among hematologist-oncologists?
  • What are the perceived clinical advantages and disadvantages of Venclexta compared with other marketed agents used for treating relapsed/refractory CLL?
  • To what extent is Venclexta currently being used by surveyed hematologist-oncologists? Where does Venclexta fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Venclexta?
  • What promotional messages are being employed by Roche/AbbVie?

Scope:

Market covered: United States.

Primary research: 74 hematologist-oncologists; qualitative interviews with 10 respondents.

Indication coverage: Relapsed/refractory CLL.

Table of contents

  • Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Emerging Therapies - Venclexta Launch Tracking (US) Wave 1
    • Key Findings
      • Benchmarking Venclexta Launch Success vs. the Competition
        • The Vast Majority of Surveyed Physicians Expressed Aided Awareness of Venclexta One Month Postlaunch
      • Prescriber and Nonprescriber Profiles
        • Who Is the Venclexta Prescriber?
        • Differences Between Venclexta Prescriber and Nonprescriber Profiles
      • Venclexta Awareness and Perceptions
        • Unaided and Aided Awareness of Venclexta
          • While Most Surveyed Physicians Were Aware of Venclexta, Some Were Unsure of the Drug's Monthly Cost and Dosing Interval
          • Unaided Awareness of Drugs for the Treatment of CLL
          • Awareness of Venclexta
          • Physician Perception of Venclexta's Approved Indications
          • Physician Perception of Venclexta's Administration
          • Physician Perception of Venclexta's Dosing Schedule
          • Awareness of Venclexta's Price
          • Perceived Price of Venclexta
          • Physician Quotes on the Perceived Advantages and Disadvantages of Venclexta
        • Familiarity with Venclexta
          • Mean Level of Familiarity with Venclexta
        • Sources of Familiarity with Venclexta
          • Venclexta Sources of Familiarity
          • Other Sources of Familiarity with Venclexta
        • Initial Reaction to and Interest in Venclexta
          • Venclexta Product Profile
          • When Presented with the Drug's Clinical Profile, Hematologist-Oncologists Show a Moderately or Highly Favorable Reaction to Venclexta
          • Initial Reaction to Venclexta
          • Interest in Venclexta
          • Physician Quotes on Initial Reaction to and Interest in Venclexta
        • Impressions of Venclexta
          • Awareness of Venclexta Profile
          • Venclexta Attributes of Which Hematologist-Oncologists Were Unaware
          • Uniqueness of Venclexta
          • Value of Venclexta Characteristics
          • Risk/Benefit Perception of Venclexta
          • Physician Quotes on Impressions of Venclexta
        • Prescriber and Nonprescriber Profiles
        • Venclexta Trial and Use
          • Willingness to Prescribe Venclexta
            • Physician Willingness to Prescribe Venclexta to Relapsed/Refractory CLL Patients with Del(17p)
            • Impact of Select Attributes on Physician Willingness to Prescribe Venclexta
            • Impact of Venclextau2019s Accelerated Approval Based on ORR Data on Physician Likelihood to Prescribe
            • Physician Quotes on Willingness to Prescribe Venclexta
          • Number of Patients Currently Receiving Venclexta
            • Patient Share in the Second-Line CLL Del(17p) Setting, Now and in Five Monthsu2019 Time
            • Patient Share in the Third-Line CLL Del(17p) Setting, Now and in Five Monthsu2019 Time
            • Venclexta Prescription Rate
            • Venclexta Discontinuation Rate Among Prescribers
            • Reasons for Discontinuing Venclexta Treatment
            • Venclexta Prescribing Practices
            • Treatment Prior to Switching to Venclexta
            • Reasons for Prescribing Venclexta
            • Primary Obstacles Deterring Physicians from Prescribing Venclexta to More R/R CLL Patients with Del(17p)
            • Treatment Selection Following Venclexta Discontinuation
            • Patient Inquiries Regarding Venclexta in Past Month
            • Hematologist-Oncologist Action Based on Specific Patient Inquiries
          • Reasons for Not Yet Prescribing Venclexta
            • Other Reasons for Not Yet Prescribing Venclexta
            • Key Reasons for Not Yet Prescribing Venclexta
            • Physician Quotes on Reasons for Not Prescribing Venclexta
          • Anticipated Venclexta Use
            • Anticipated Venclexta Use Among Nonprescribers
            • Percentage of Second-Line and Third-Line CLL Patient Eligible for Venclexta
            • Potential Displacement of Existing Treatments by Venclexta
            • Rituxan-Based Therapies Likely to Be Replaced by Venclexta
            • Physician Quotes on Anticipated Venclexta Use
          • Venclexta Performance on Key Attributes
            • Overall Level of Satisfaction with Venclexta for the Treatment of Relapsed/Refractory CLL with Del(17p)
            • Level of Satisfaction with Venclexta on Key Metrics
            • Physician Rating of Venclexta on Key Attributes
            • Performance of Venclexta on Key Attributes
        • Effectiveness of Face-to-Face Detailing for Venclexta
          • Venclexta Sales Representative Frequency and Reach
            • Last Time of Contact with a Venclexta Representative
            • Physician Quotes on Venclexta Sales Representative Frequency and Reach
          • Satisfaction with Venclexta Sales Representatives
            • Sales Representative Performance on Key Attributes
          • Venclexta Message Recall
            • Topics Discussed by Sales Representative
            • Positioning of Venclexta Against Other Products
        • Appendix
          • Abbreviations

        launch Related Market Assessment Reports